In this phase I trial, Lai and colleagues evaluated the safety and toxicity of EGFR antisense DNA therapy in 20 patients with advanced squamous-cell carcinoma of the head and neck. All patients ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Scientists use short oligonucleotides as primers for polymerase chain reaction and next-generation sequencing, in DNA microarrays and fluorescence in situ hybridization, and in antisense therapies. (1 ...

LCGC International spoke with Daniel Meston and Dwight Stoll from Gustavus Adolphus College in St. Peter, Minnesota, USA, ...

The immunomodulatory character of bacterial CpG DNA is well known ... they explained the immunostimulatory properties of certain antisense oligonucleotides, which had not fit into any prevailing ...

These informational drugs, known as antisense therapies, chemically modify genetic sequences to reach specific targets and block disease-associated mRNA. Agrawal likens these therapies to “genetic ...

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note released on Wednesday morning. The brokerage issued a sell rating on the stock. Bio-Path Stock Down 5.